Search PubMedSearch

PubMed · 8932972

Statistical methods for cost-effectiveness analyses.

Abstract

A statistical framework is presented for examining cost and effect data on competing interventions obtained from an RCT or from an observational study. Parameters of the join distribution of costs and effects or a regression function linking costs and effects are used to define cost-effectiveness (c-e) measures. Several new c-e measures are proposed that utilize the linkage between costs and effects on the patient level. These measures reflect perspectives that are different from those of the commonly used measures, such as the ratio of expected cost to expected effect, and they can lead to different relative rankings of the interventions. The cost-effectiveness of interventions are assessed statistically in a two stage procedure that first eliminates clearly inferior interventions. Members of the remaining admissible set are then rank ordered according to a c-e preference measure. Statistical techniques, particularly in the multivariate normal case, are given for several commonly used c-e measures. These techniques provide methods for obtaining confidence intervals, for testing the hypothesis of admissibility and for the equality of interventions, and for ranking interventions. The ideas are illustrated for a hypothetical clinical trial of antipsychotic agents for community-based persons with mental illness.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Siegel, E Laska, M Meisner. 1996. Statistical methods for cost-effectiveness analyses.. https://doi.org/10.1016/s0197-2456(95)00259-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment].

The great diversity of schizophrenic symptoms rules out one simple etiological explanation. However,impairment of information processing, including disruption of sensorimotor gating, is a consistent finding in schizophrenic patients. Dysfunction in sensorimotor gating is believed to be the result of different developmentally or environmentally caused disturbances involving the neural trajectories involved in information processing. Psychopathology and cognition will depend on the primary involvement of distinct parts of these circuits and on secondarily derived time-dependent disturbances of transmitter function. This review is focused on clinical and preclinical evidence for the impact of interactions between glutamatergic, dopaminergic, serotonergic and noradrenergic brain systems on cognitive performance. The hypothetical consequences of transmitter dysfunction for progressive development of impairment in sensorimotor gating are illustrated. Finally, the broad receptor profile of second generation antipsychotics is analysed to explain the clinical improvement in neurocognition that may occur during treatment with such drugs.

Antipsychotic Agents